Claim Missing Document
Check
Articles

Found 22 Documents
Search

IDENTIFIKASI Taenia solium PADA FESES WARGA DESA KARANG LANGIT DENGAN KEBIASAAN KONSUMSI DAGING BABI Dian Nurmansyah; Javercintya Angelica Maramis; Puspawati Puspawati Puspawati
Jurnal Kajian Ilmiah Kesehatan dan Teknologi Vol. 5 No. 2 (2023)
Publisher : Politeknik Unggulan Kalimantan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52674/jkikt.v5i2.109

Abstract

Taenia solium is a parasite class of cestode lives in the small intestine of humans to get the nutrition of its life. Humans are definitive host and intermediate host is pigs. Taenia solium infection is often found in areas where a lot consumed of raw or undercooked pork that contains cysticercus, or in areas with poor sanitation. If humans ingest proglottid or Taenia solium eggs, cysticercus cellulose larvae can grow in the host. This research was conducted of Karang Langit village on March 2021, the type of research used was survey descriptive with a cross sectional research design. The aim of this study to aware the presence of Taenia solium infection in the feces of the village. The research method used is native method. Based on the results of the research, no progglotid were found, nevertheless was found eggs of Taenia solium by 2,25%
Re-evaluating Albendazole-Based Preventive Chemotherapy for Soil-Transmitted Helminths in Indonesia: A Narrative Review on Efficacy, Challenges, and Future Strategies Lala Gunasari; Dian Nurmansyah; Dessy Triana
Sciences and Clinical Pharmacy Research Journal Vol. 3 No. 1 (2026): April
Publisher : Indonesian Journal Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47134/scpr.v3i1.5601

Abstract

This narrative review seeks to critically analyze the efficacy of albendazole, the cornerstone anthelmintic of the program. Relevant literature (2020-2025) was identified through a systematic search of the ScienceDirect and Google Scholar databases. While evidence confirms albendazole's effectiveness, with cure rates up to 93%, its performance is inconsistent and influenced by a confluence of factors. A critical constraint identified is the absence of robust, large-scale national surveillance data on STH prevalence and drug efficacy, hindering a comprehensive assessment of albendazole's performance within the program. The persistent burden of STH underscores a gap between program implementation and its intended public health impact. While albendazole remains essential, its variable efficacy and operational barriers necessitate a critical reassessment of the current strategy.